Systemic application of type I IFNs in tumor therapy to enhance CD8 T-cell responses is, however, only resulting in short-term anti-tumor action because of negative effects during prolonged IFN signaling by inducing immunosuppressive factors such as PD-L1 and IL-10 (Zhou et al., 2020). The gene discussed is IFNA1; the disease is neoplasm.